

Dmitriy A Kudlay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8080545/publications.pdf>

Version: 2024-02-01

131
papers

970
citations

586496

16
h-index

620720

26
g-index

139
all docs

139
docs citations

139
times ranked

1116
citing authors

#	ARTICLE	IF	CITATIONS
1	Complicated course of COVID-19 in a child with Bloch-Sulzberger syndrome. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2022, 66, 103-107.	0.1	0
2	Impact of Active Case Finding on Clinical Structure and Severity of Tuberculosis in School-Aged Children (7-15 Years Old). Tuberculosis and Lung Diseases, 2022, 100, 26-32.	0.2	2
3	Molecular and Cellular Mechanisms of M. tuberculosis and SARS-CoV-2 Infections—Unexpected Similarities of Pathogenesis and What to Expect from Co-Infection. International Journal of Molecular Sciences, 2022, 23, 2235.	1.8	9
4	COVID-19 Vaccines: An Overview of Different Platforms. Bioengineering, 2022, 9, 72.	1.6	32
5	The clinical use and cost-effectiveness of domestic blood coagulation factors VIII and IX. Pediatric Hematology/Oncology and Immunopathology, 2022, 21, 72-82.	0.1	0
6	TREC/KREC Levels and T and B Lymphocyte Subpopulations in COVID-19 Patients at Different Stages of the Disease. Viruses, 2022, 14, 646.	1.5	18
7	Tuberculosis and autoimmunity: Common features. Tuberculosis, 2022, 134, 102202.	0.8	10
8	ROLE OF FIBROBLAST GROWTH FACTORS 19, 21 AND THE KLOTHO PROTEIN IN THE DEVELOPMENT OF INSULIN RESISTANCE AND OBESITY IN CHILDREN. Pediatria, 2022, 101, 86-91.	0.1	0
9	Ethical aspects of clinical trials of blood clotting factors in children with hemophilia. , 2022, , .		0
10	Analysis of the TREC and KREC Levels in the Dried Blood Spots of Healthy Newborns with Different Gestational Ages and Weights. , 2022, 14, 101-108.		0
11	ESAT-6 and CFP-10 antigens as a biotechnology molecule substrate. Applications in medicine. Russian Journal of Infection and Immunity, 2022, 12, 439-449.	0.2	2
12	Anti-inflammatory effect of siRNAs targeted IL4 and IL13 in a mouse model of allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2829-2832.	2.7	2
13	TREC and KREC as prognostic markers of HIV infection and COVID-19. Tuberculosis and Lung Diseases, 2022, 100, 6-13.	0.2	0
14	CONTINUOUS GLUCOSE MONITORING TECHNOLOGY IN HEALTHY INDIVIDUALS: NEW OPPORTUNITIES FOR PREVENTIVE MEDICINE. Pediatria, 2022, 101, 205-211.	0.1	0
15	Blood pressure variability and brain neuroimaging in patients with type 2 diabetes. Zhurnal Nevrologii I Psikiatrii Imeni S S Korsakova, 2022, 122, 90.	0.1	0
16	Screening for tuberculosis of patients with HIV-infection. New possibilities. Acta Biomedica Scientifica, 2022, 7, 83-90.	0.1	0
17	Age-Related Changes in the Fibroblastic Differentiation of the Dermis: Role in Skin Aging. International Journal of Molecular Sciences, 2022, 23, 6135.	1.8	13
18	Efficacy of using bedaquiline in treatment of tuberculosis patients with multiple and extensive drug resistance. Tuberculosis and Lung Diseases, 2022, 100, 56-63.	0.2	8

#	ARTICLE	IF	CITATIONS
19	Molecular Mechanisms of Changes in Homeostasis of the Dermal Extracellular Matrix: Both Involuntional and Mediated by Ultraviolet Radiation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6655.	1.8	14
20	The clinical case: COVID-19 in a child with chronic kidney disease. <i>Russian Journal of Infection and Immunity</i> , 2022, 12, 585-590.	0.2	0
21	Past, present, and future of allergen immunotherapy vaccines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 131-149.	2.7	66
22	ARIAબI statement on asthma and COVIDꤙ (June 2, 2020). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 689-697.	2.7	57
23	Respiratory syncytial virus upregulates IL-33 expression in mouse model of virus-induced inflammation exacerbation in OVA-sensitized mice and in asthmatic subjects. <i>Cytokine</i> , 2021, 138, 155349.	1.4	7
24	IgE©reactivity profiles to allergen molecules in Russian children with and without symptoms of allergy revealed by microચrray analysis. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 251-263.	1.1	16
25	Osteopontin as a factor of neuroinflammation in chronic non-infectious diseases. <i>Molekulyarnaya Meditsina (Molecular Medicine)</i> , 2021, 19, 27-31.	0.0	0
26	Bioimpedance analysis as a promising screening technology in children. <i>Vrach</i> , 2021, 32, 32-37.	0.0	1
27	Molecular immunological aspects of diagnostics, prevention and treatment of coronavirus infection. <i>Immunologiya</i> , 2021, 42, 198-210.	0.1	14
28	PU.1 is a nuclear factor of immunocompetent cells of tumor stroma in colorectal cancer. <i>Clinical and Experimental Morphology</i> , 2021, 10, 32-39.	0.1	2
29	The use of the ELISPOT technological platform in the diagnosis of tuberculosis infection in patients with HIV infection. <i>Immunologiya</i> , 2021, 42, 395-402.	0.1	3
30	Hybrid proteins CFP10 and ESAT6. A path from developing a molecule to population screening for TB infection. <i>Immunologiya</i> , 2021, 42, 166-174.	0.1	2
31	Soluble forms of immune checkpoints in ovarian cancer. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 80-86.	0.2	0
32	Immunogenetic Predictors of Severe COVID-19. <i>Vaccines</i> , 2021, 9, 211.	2.1	40
33	TUBERCULOSIS UNDER CONDITIONS OF NOVEL CORONAVIRUS INFECTION. <i>Pediatrics</i> , 2021, 100, 153-157.	0.1	1
34	RESULTS OF THE OPEN MULTICENTER PROSPECTIVE CLINICAL STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF MOROCTOCOG ALPHA IN 6 TO 12 YEAR OLD CHILDREN WITH HEMOPHILIA A. <i>Pediatrics</i> , 2021, 100, 236-245.	0.1	1
35	Assisted reproductive technologies and children's health parameters. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2021, 20, 218-221.	0.1	1
36	Mesenchymal multipotent stromal cells and cancer safety: two sides of the same coin or a double-edged sword (review of foreign literature). <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2021, 8, 64-84.	0.1	1

#	ARTICLE	IF	CITATIONS
37	Stenotic remodeling of coronary vessels in the elderly patients with high cardiovascular risk and the presence of multifocal atherosclerosis. <i>Cardiosomatics</i> , 2021, 12, 15-22.	0.2	0
39	NON-INVASIVE FIBROGENESIS MARKERS IN CHILDREN WITH ACUTE AND CHRONIC SECONDARY PYELONEPHRITIS. <i>Pediatrics</i> , 2021, 100, 88-96.	0.1	1
40	Scientific platform, development and implementation of effective immunodiagnosis of tuberculosis infection in the Russian Federation. <i>Meditsinskii Akademicheskii Zhurnal</i> , 2021, 21, 75-84.	0.2	2
41	Pharmacoepidemiology and pharmacoconomics of multidrug- and extensively drug-resistant tuberculosis. <i>Farmakoekonomika</i> , 2021, 14, 235-248.	0.4	13
42	Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. <i>Life</i> , 2021, 11, 753.	1.1	14
43	Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab. <i>Annals of Hematology</i> , 2021, 100, 2689-2698.	0.8	15
44	Diagnostics and management of tuberculosis and COVID-19 in a patient with pneumothorax (clinical) <i>Tuberculosis</i> , 2021, 100, 1000000.	0.8	4
45	POSSIBILITIES OF A LABORATORY TEST BASED ON THE DETERMINATION OF THE T-CELL RESPONSE TO STIMULATION WITH SPECIFIC CFP10 AND ESAT6 ANTIGENS IN THE DETECTION OF TUBERCULOSIS INFECTION IN CHILDREN AND ADOLESCENTS. <i>Pediatrics</i> , 2021, 100, 128-132.	0.1	0
46	Clinical and prognostic significance of the soluble form of the VISTA immunity control point in patients with primary bone tumors. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 533-538.	0.2	1
47	MICROBIOLOGICAL CHARACTERISTICS OF PATHOGENIC FLORA IN CHILDREN WITH ACUTE AND CHRONIC PYELONEPHRITIS. <i>Pediatrics</i> , 2021, 100, 131-137.	0.1	0
48	SPECIFICITY OF THE MOROCTOCOG ALPHA MOLECULE: RESULTS OF A PROSPECTIVE, MULTICENTER, OPEN-LABEL, OBSERVATIONAL STUDY OF EFFICACY AND SAFETY IN CHILDREN AGED 12 TO 18 YEARS WITH HEMOPHILIA A. <i>Pediatrics</i> , 2021, 100, 159-169.	0.1	2
49	Reference values for TREC and KREC concentrations in adults. <i>Vrach</i> , 2021, 32, 21-28.	0.0	1
50	Immunotherapy in the Treatment of COVID-19. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2021, 20, 158-168.	0.1	0
51	Mechanisms of stem cells action: reality and hypotheses. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2021, 8, 71-78.	0.1	0
52	Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form. <i>Pathogens</i> , 2021, 10, 1408.	1.2	61
53	Predictors of tuberculosis infection among children and adolescents with positive results of a skin test with recombinant TB allergen. <i>Meditsinskiy Sovet</i> , 2021, , 147-154.	0.1	1
54	Efficacy and safety of regimen containing bedaquiline in children with drug-resistant tuberculosis. <i>Meditsinskiy Sovet</i> , 2021, , 138-146.	0.1	3

#	ARTICLE	IF	CITATIONS
55	Oxidative stress and fertility. Nature, diagnosis, and treatment. Voprosy Ginekologii, Akusherstva I Perinatologii, 2021, 20, 131-139.	0.1	1
56	Possibilities of the Enzyme-Linked Immunospot Assay (Elispot) method in carrying out anti-tuberculosis measures in patients with HIV infection. Immunologiya, 2021, 42, 536-544.	0.1	1
57	Immunodiagnostic Tests in the Assessment of Specific Sensitization to <i>M. tuberculosis</i> in Children under the Current Epidemical Situation. Tuberculosis and Lung Diseases, 2021, 99, 47-54.	0.2	3
58	COMORBID CONDITIONS IN OBESITY IN CHILDREN AND ADOLESCENTS AND MODERN TECHNOLOGIES OF THEIR DIAGNOSIS. Pediatriia, 2021, 100, 105-112.	0.1	1
59	APPLICATION OF BRAIN NEUROIMAGING TECHNOLOGIES FOR CHILDHOOD OBESITY. Pediatriia, 2021, 100, 91-96.	0.1	1
60	Time course of changes in the list of drugs for the treatment of COVID-19 in the temporary guidelines. Vrach, 2021, 32, 29-34.	0.0	0
61	Switching to dual therapy after 24 weeks of the triple therapy of HIV infection: efficacy and safety. Infectious Diseases: News, Opinions, Training, 2021, 10, 66-75.	0.1	0
62	DYNAMICS OF MICROVESICLE FORMATION IN BLOOD IN PATIENTS WITH COVID-19 AT DIFFERENT STAGES OF THE DISEASE. , 2021, , 68-74.	0.0	3
63	Neural networks in the predictive diagnosis of cognitive impairment in type 1 and type 2 diabetes mellitus. Terapevticheskii Arkhiv, 2021, 93, 1349-1358.	0.2	0
64	Pathogenetic relationship of oral microbiota and obesity in children and adolescents. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2021, 66, 38-41.	0.1	2
65	The Role Of Osteopontin In Patients With Type 2 Diabetes And Cognitive Impairment. Russian Open Medical Journal, 2021, 10, .	0.1	0
66	Small Fiber Neuropathy in Sarcoidosis. Pathophysiology, 2021, 28, 544-550.	1.0	11
67	Russian recombinant coagulation factors: the technological background and the results of clinical studies. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 209-213.	0.1	0
68	REFERENCE VALUES FOR THE CONCENTRATION OF TREC AND KREC IN CHILDREN AGED 1â€“17 YEARS. Pediatriia, 2021, 100, 38-45.	0.1	2
69	Linear and dendrimeric antiviral peptides: design, chemical synthesis and activity against human respiratory syncytial virus. Journal of Materials Chemistry B, 2020, 8, 2607-2617.	2.9	19
70	Identification of a novel splice variant for mouse and human interleukin-5. Heliyon, 2020, 6, e03586.	1.4	2
71	Toward personalization of asthma treatment according to trigger factors. Journal of Allergy and Clinical Immunology, 2020, 145, 1529-1534.	1.5	30
72	M1-like macrophages are potent producers of anti-viral interferons and M1-associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma exacerbations. EBioMedicine, 2020, 54, 102734.	2.7	37

#	ARTICLE	IF	CITATIONS
73	New Coronaviral Infection: Features of Clinical Course, Capabilities of Diagnostics, Treatment and Prevention in Adults and Children. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2020, 19, 123-131.	0.1	30
74	Prospects for a COVID-19 treatment: review. <i>Translational Medicine</i> , 2020, 7, 30-37.	0.1	7
75	Possibilities for correcting hepatotoxic reactions during therapy in patients with COVID-19 (case) <i>Tj ETQq1 1 0.784314 rgBT /Overloc</i>	0.1	4
76	Immune status of children with complications of BCG/BCG-M vaccination. <i>Tuberculosis and Lung Diseases</i> , 2020, 98, 27-34.	0.2	6
77	BCG vaccination as protection from COVID-19: epidemiological and molecular biological aspects. <i>Tuberculosis and Lung Diseases</i> , 2020, 98, 6-14.	0.2	4
78	Biomarkers and immunological tests. Experimental and clinical parallels of latent tuberculosis infection. <i>Tuberculosis and Lung Diseases</i> , 2020, 98, 63-74.	0.2	25
79	Gaucher disease in children: what has changed in the 21st century. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2020, 6, 19-24.	0.1	1
80	RECOMBINANT TUBERCULOSIS ALLERGEN: 10 YEARS OF EXPERIENCE WITH THE TEST IN CHILDREN AND ADOLESCENTS IN THE RUSSIAN FEDERATION (META-ANALYSIS DATA). <i>Pediatriia</i> , 2020, 99, 121-129.	0.1	29
81	Diagnosis of COVID-19. Methods and problems of virus SARS-CoV-2 detection under pandemic conditions. <i>Vrach</i> , 2020, 31, 5-10.	0.0	7
82	Hepatoprotective properties of glycyrrhizic acid. <i>Ekspierimental'naya I Klinicheskaya Gastroenterologiya</i> , 2020, , 96-108.	0.1	5
83	Promising compounds from natural sources against COVID-19. <i>Russian Journal of Allergy</i> , 2020, 17, 18-32.	0.1	1
84	NEONATAL SCREENING FOR PRIMARY IMMUNODEFICIENCY AND $\delta\epsilon$ - β - CELL LYMPHOPENIA AS THE BASIS FOR THE FORMATION OF RISK GROUPS FOR CHILDREN WITH CONGENITAL PATHOLOGIES. <i>Pediatriia</i> , 2020, 99, 8-15.	0.1	3
85	Autoimmune component in the etiology of sarcoidosis. <i>Tuberculosis and Lung Diseases</i> , 2020, 98, 54-62.	0.2	6
86	FEATURES OF CLINICAL STUDIES OF RECOMBINANT COAGULATION FACTORS $\text{ID}\Phi$ IN CHILDREN WITH HEMOPHILIA D' . <i>Pediatriia</i> , 2020, 99, 168-175.	0.1	0
87	Dornase alfa in the treatment of COVID-19: destruction of neutrophil extracellular traps. <i>Pulmonologiya</i> , 2020, 30, 344-349.	0.2	3
88	DIAGNOSTIC SIGNIFICANCE OF AUTOANTIBODIES IN CHILDHOOD CARBOHYDRATE METABOLISM DISORDERS. <i>Pediatriia</i> , 2020, 99, 209-218.	0.1	0
89	ESTIMATION OF HEMORRHAGIC SYNDROME IN PATIENTS WITH HEMOPHILIA A DURING PROFILACTIC AND ON DEMAND TREATMENT WITH OCTOFACTOR. <i>Pediatriia</i> , 2020, 99, 88-93.	0.1	0
90	INNOVATIVE TECHNOLOGIES FOR DETECTING AND DIAGNOSTIC OF TUBERCULOSIS IN CHILDREN AND ADOLESCENTS: ACHIEVEMENTS AND PROBLEMS. <i>Pediatriia</i> , 2020, 99, 112-118.	0.1	1

#	ARTICLE	IF	CITATIONS
91	PLACE OF IGRA TESTS (TESTS FOR INTERFERON-GAMMA DETERMINATION) IN TUBERCULOSIS INFECTION DIAGNOSIS. <i>Pediatriia</i> , 2020, 99, 231-235.	0.1	2
92	Preventive Tuberculosis Services Reduces the Risk of Local Forms of Tuberculosis Development in Children on Immunosuppressive Therapy: Retrospective Cohort Study. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2020, 19, 346-351.	0.1	1
93	RESULTS OF AN OPEN, PROSPECTIVE, MULTICENTER, NONCOMPARATIVE STUDY OF THE PHARMACOKINETICS, EFFICACY AND SAFETY OF NONACOG ALFA IN PATIENTS AGED 6â€“12 YEARS WITH SEVERE AND MODERATE HEMOPHILIA B. <i>Pediatriia</i> , 2020, 99, 190-198.	0.1	0
94	Xenon gas therapy of placental insufficiency in pregnant women. A look from the future. <i>Voprosy Ginekologii, Akusherstva I Perinatologii</i> , 2020, 19, 35-42.	0.1	0
95	Heart dysfunction against the background of atypical hemolytic-uremic syndrome in obstetric practice. <i>Voprosy Ginekologii, Akusherstva I Perinatologii</i> , 2020, 19, 114-122.	0.1	0
96	Features carbohydrate metabolism disorders on the background of obesity in children and teenagers. <i>Vrach</i> , 2020, 31, 78-83.	0.0	1
97	Pregnancy-associated atypical hemolytic-uremic syndrome: is pregnancy to blame or its complications?. <i>Voprosy Ginekologii, Akusherstva I Perinatologii</i> , 2020, 19, 81-91.	0.1	0
98	Evaluation of the efficacy and safety of the biosimilar drug Glurazyme (imiglucerase) in patients with Gaucher disease type 1. <i>Gematologiya I Transfuziologiya</i> , 2020, 65, 8-23.	0.1	1
99	IMMUNOGENICITY STUDY OF THE RUSSIAN RECOMBINANT ACTIVATED COAGULATION FACTOR VII IN HEMOPHILIA A PATIENTS WITH INHIBITORS. <i>Pediatriia</i> , 2020, 99, 206-215.	0.1	0
100	SCREENING FOR TUBERCULOSIS INFECTION WITH VARIOUS OPTIONS FOR THE USE OF RECOMBINANT TUBERCULOSIS ALLERGEN IN CHILDREN AND ADOLESCENTS IN MOSCOW. <i>Pediatriia</i> , 2020, 99, 136-146.	0.1	2
101	Eculizumab in the treatment of complement system disorders including paroxysmal nocturnal hemoglobinuria. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2020, 19, 193-199.	0.1	0
102	Biotechnological products for the treatment of complement system disorders including paroxysmal nocturnal hemoglobinuria: currently available and in development. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2020, 19, 164-172.	0.1	0
103	Biochemical and morphometric methods for assessing cognitive impairment in patients with type 2 diabetes. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 2636.	0.4	0
104	DIFFICULTIES IN TREATMENT CHOICE FOR THE PATIENT WITH SEVERE COURSE OF PAUCIARTICULAR JUVENILE ARTHRITIS ASSOCIATED WITH HLA-B27 ANTIGEN. <i>Pediatriia</i> , 2020, 99, 244-249.	0.1	1
105	Tracing IgE-Producing Cells in Allergic Patients. <i>Cells</i> , 2019, 8, 994.	1.8	31
106	Bet v lâ€“specific IgE levels and PRâ€“10 reactivity discriminate silent sensitization from phenotypes of birch allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2525-2528.	2.7	20
107	Diversity of PEGylation methods of liposomes and their influence on RNA delivery. <i>MedChemComm</i> , 2019, 10, 369-377.	3.5	79
108	Phase III Clinical Trial of ElizariaÂ® and SolirisÂ® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data. <i>Blood</i> , 2019, 134, 3748-3748.	0.6	17

#	ARTICLE	IF	CITATIONS
109	EFFICACY OF NEW METHODS OF TUBERCULOSIS INFECTION IMMUNODIAGNOSTICS IN THE RUSSIAN FEDERATION. <i>Pediatrriia</i> , 2019, 98, 229-235.	0.1	20
110	DEVELOPMENT AND USE OF RUSSIAN RECOMBINANT BLOOD COAGULATION FACTOR VII, VIII, IX DRUGS IN CHILDREN WITH HEMOPHILIA A AND B. <i>Pediatrriia</i> , 2019, 98, 9-17.	0.1	5
111	MONITORING OF TUBERCULOSIS INFECTION IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS RECEIVING GENETICALLY PREPARATIONS. <i>Pediatrriia</i> , 2019, 98, 209-213.	0.1	2
112	C1-ESTERASE INHIBITOR: APPROACHES TO RATIONAL PHARMACOTHERAPY OF NEONATAL SEPSIS. <i>Pediatrriia</i> , 2019, 98, 188-194.	0.1	1
113	TUBERCULOSIS IN CHILDREN IN THE NORTH-WEST REGION OF THE RUSSIAN FEDERATION: EPIDEMIOLOGY AND DIAGNOSTIC MEASURES EFFICACY. <i>Pediatrriia</i> , 2019, 98, 274-279.	0.1	2
114	SCREENING OF NEWBORNS FOR PRIMARY IMMUNODEFICIENCIES AND RISK GROUPS FOR IMMUNOREGULATORY DISORDERS REQUIRING FOLLOW-UP. <i>Pediatrriia</i> , 2019, 98, 49-54.	0.1	1
115	Research of adaptation mechanisms of regulation of microcirculatory beds in patients with hemophilia. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2019, 6, 54-58.	0.1	1
116	LATENT TUBERCULOSIS INFECTION IN CHILDREN AS A PREREQUISITE FOR THE TUBERCULOSIS DEVELOPMENT IN ADULTS. <i>Pediatrriia</i> , 2019, 98, 179-181.	0.1	0
117	EXPERIENCE OF USING TECHNOLOGIES FOR REMOTE MONITORING OF TYPE 1 DIABETES MELLITUS AT THE STAGE OF OUTPATIENT HEALTHCARE. <i>Pediatrriia</i> , 2019, 98, 219-224.	0.1	0
118	THE EXPERIENCE OF USING ELIZARIA FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME. <i>Pediatrriia</i> , 2019, 98, 225-229.	0.1	3
119	PECULIARITIES OF CLINICAL STUDIES OF RECOMBINANT COAGULATION FACTORS VIII IN CHILDREN WITH HEMOPHILIA A. <i>Pediatrriia</i> , 2019, 98, 103-110.	0.1	0
120	Dornasum alfa IN TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS. <i>Pediatrriia</i> , 2019, 98, 111-117.	0.1	4
121	Results of a phase I open randomized comparative crossover clinical trial to assess the safety and pharmacokinetics of GlurazimÂ® (imiglucerase) in comparison with the reference product in healthy volunteers. <i>Oncogematologiya</i> , 2019, 14, 73-83.	0.1	3
122	Effect of lipopeptide structure on gene delivery system properties: Evaluation in 2D and 3D in vitro models. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 167, 328-336.	2.5	10
123	The role of immunological tests in the diagnosis of tuberculosis infection in children with juvenile idiopathic arthritis (JIA). , 2018, , .		14
124	Accompanying therapy of patients with extensive drug-resistant (xdr) lung tuberculosis. , 2018, , .		2
125	Long-Term Prophylaxis with Activated Recombinant FVII in Children with Hemophilia a and Inhibitor, Receiving Treatment with ITI Protocol. <i>Blood</i> , 2016, 128, 4980-4980.	0.6	2
126	Detection TB infection using a skin tests with tuberculin and allergen recombinant (CFP-10-ESAT-6) in children and adolescents in Moscow in 2015. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
127	Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B. Blood, 2015, 126, 3532-3532.	0.6	4
128	Safety and Efficiency of New Nonacog Alfa Drug in the Treatment of Bleeding Episodes in Patients with Severe and Moderate Hemophilia B. Blood, 2015, 126, 4690-4690.	0.6	2
129	Effectiveness of tuberculosis detection using a skin test with allergen recombinant (CFP-10-ESAT-6) in children. , 2015, , .		14
130	The Pharmacokinetic Properties, Safety and Tolerability of a New Nonacog Alfa (Innonafactor) in Patients with Hemophilia B. Blood, 2015, 126, 4691-4691.	0.6	2
131	Safety and Efficacy of New Moroctocog Alfa Drug (Octofactor) in Prophylactic Treatment in Adolescent Patients with Severe and Moderate Hemophilia a. Blood, 2015, 126, 4703-4703.	0.6	4